drugset / Trial / NCT00739206

Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.

NCT00739206

Phase 2 Terminated 113 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of the study is to assess the efficacy and safety of SAR97276A in severe malaria in pediatric patients. Before treating pediatric patients with severe malaria, the efficacy and safety of SAR97276A will be first tested in adult patients, then in pediatric patients, with uncomplicated malaria. The safety and the concentration of SAR97276A in blood and plasma will be assessed in adult and pediatric patients.

Timeline

Start
2008-08
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ALBITIAZOLIUM Small molecule 0.14 mg/kg Intramuscular
Subject ALBITIAZOLIUM Small molecule 0.18 mg/kg Intramuscular

Indications